Aerocrine is a medical technology company focused on improving the treatment of patients with inflamed airways. Measuring airways inflammation helps doctors to diagnose, monitor and optimise therapy for people with inflammatory airway diseases.
The founders of Aerocrine emerged from the highly prestigious Karolinska Institute in Sweden where they were the first to identify nitric oxide (NO) as a marker of inflammation. Aerocrine has taken this significant discovery from laboratory to listed company and is now established in some of the world’s largest markets. The company markets NIOX MINO and NIOX VERO, two highly reliable and effective tools to assist in the diagnosis and control of airways disease.
Aerocrine will continue to develop products to improve the quality of life, management and care of people with airways inflammatory disease.